Accessibility StatementSkip Navigation "This newly issued patent further demonstrates the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this patent further strengthens our ability to pursue strategic global opportunities in regions with a high incidence of breast cancer." A Phase 1 clinical trial of Anixa's breast cancer vaccine has been recently completed and Cleveland Clinic wil ...